- Zacks•16 days ago
Arena Pharmaceuticals, Inc. (ARNA) announced that it has amended the marketing and supply agreement with Eisai Co., Ltd. (ESALY) for Belviq.
- PR Newswire•17 days agoGerman Institute for Quality and Efficiency in Health Care (IQWiG) Confirms Additional Benefit for Kisplyx® (lenvatinib) in Combination with everolimus for the Treatment of Advanced Renal Cell Carcinoma
HATFIELD, England, January 4, 2017 /PRNewswire/ -- FOR EU MEDIA ONLY: NOT FOR SWISS/ AUSTRIAN MEDIA Approximately 15,000 people in Germany develop renal cell carcinoma every year. The German Institute ...
- PR Newswire•18 days agoFirst-in-class Epilepsy Treatment Fycompa® (perampanel) Launches in Jordan, Kingdom of Saudi Arabia and the United Arab Emirates
HATFIELD, England, January 4, 2017 /PRNewswire/ -- Fycompa ® (perampanel) is now licensed for adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures in Jordan, ...
ESALY : Summary for EISAI CO SPON ADR REP 1 COM NPV - Yahoo Finance
Eisai Co., Ltd. (ESALY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||55.72 - 56.94|
|52 Week Range||53.55 - 66.38|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||25.53|
|Dividend & Yield||1.26 (2.20%)|
|1y Target Est||N/A|